Author: admin

  • The Coral documentary ‘a coming-of-age portrait’

    The Coral documentary ‘a coming-of-age portrait’

    Sarah Spina-MatthewsBBC News, Liverpool

    BBC James Skelly and Nick Power sit side by side on a sofa. Skelly holds a corduroy hat in one hand and Power wears a cap and has his hands clasped. BBC

    James Skelly and Nick Power of Wirral band The Coral

    A new documentary about Merseyside indie band The Coral is a “coming-of-age portrait of six friends”, its director has said.

    Dreaming of You: The Making of The Coral, had its premiere screening on The Wirral, where the band is from, on Friday at The Light cinema ahead of its nationwide release on 12 September.

    Director James Slater said the film, which is narrated by the band, follows The Coral’s six original members from their childhood in Hoylake to becoming “this really influential band”.

    He said: “For me, The Coral are a little bit unheralded in terms of the influence they’ve had on many bands, many artists.”

    “There was something different about them, they had their own inner language,” he said.

    The Coral, who were formed in 1996 and became a five-piece after the departure of guitarist Bill Ryder-Jones in 2008, broke on to the British indie music scene with their single Dreaming of You in 2002 from their Mercury Music Prize-nominated debut album.

    ‘Our own world’

    They were also nominated for three Brit Awards, and have gone on to release 12 albums.

    Frontman James Skelly said the film featured archival footage the band filmed themselves over years, which captured the importance of their friendship.

    “It was more about the friendship than anything else,” he said.

    “Music was just a by-product.”

    Skelly said the group came together because they did not fit in anywhere else when they were growing up.

    He said: “We were the freaks that the freaks did want to hang around with.

    “We weren’t quite lads, but we weren’t quite art school or trust fund kids, so we had our own little world.”

    Skelly said, as well as friendship, the band’s home had also been a major influence on the music.

    “There’s something about the twitching curtain aspect of suburbia I’ve always been drawn to in art,” he said.

    “And I could never be away from the sea, I think I’d feel its call wherever I went.”

    Continue Reading

  • London faces first Tube strike since March 2023

    London faces first Tube strike since March 2023

    London Underground staff have started a five-day walkout over pay and conditions.

    Members of the Rail, Maritime and Transport (RMT) union are carrying out rolling action over pay and fatigue management, and have asked for a 32-hour week.

    There will be limited service until 18:00 BST on Sunday and little or no service between Monday and Thursday. The Elizabeth line and the Overground will operate as normal but are expected to be much busier, along with buses and roads.

    Transport for London (TfL) has offered a 3.4% pay rise and said it “welcomes further engagement with our unions”, but said a reduction in the contractual 35-hour week “is neither practical nor affordable”.

    Continue Reading

  • The Poole church pulling in music lovers for gigs in the nave

    The Poole church pulling in music lovers for gigs in the nave

    Steve HarrisBBC News, Parkstone, Poole

    @clopezphotography Annie and the Caldwells performing on stage with the singer in a blue top holding a microphone to her mouth and a bass guitarist in the background@clopezphotography

    Annie and the Caldwells appeared at the church in August

    “Music is the heart and soul of this place,” says Reverend Mike Trotman as he reflects on his church being used as a venue for midweek live gigs.

    The 19th Century St Peter’s Church in Parkstone, Poole, has been hosting a series of sell-out gigs with performers on a stage on the nave, under its large vaulted ceiling.

    At a time when musicians are struggling with a lack of venues, it introduces a 400-seat-capacity setting to the local music scene.

    Rev Trotman admitted the idea “raised a few eyebrows” when he was initially approached by a music promoter.

    The collaboration with the Warm agency has brought artists such as acclaimed Mississippi family band Annie and the Caldwells and Watford indie folk-duo, The Staves.

    @clopezphotography A wide view of The Staves performing at the front of the church with stone arches behind them and a full seated audience in the foreground@clopezphotography

    The church has hosted a series of sell-out concerts

    Although the vicar described himself as a music lover, he insisted the “right” kind of music was needed in the church.

    “Maybe thrash metal is a no,” he said.

    He said the church has been “flourishing” since the series began.

    “I think it actually deepens our role because it enhances the beauty, the sense of gathering, and the sense of being a community in this space.

    “I’m not going to lie, it does put some money in the coffers and it helps to actually sustain us as a functioning church, and it keeps the show on the road on Sundays.”

    Classed as a major parish church, its size means St Peter’s is known locally as “Poole’s cathedral”.

    “It’s designed to create a sense of awe and wonder as we look down the nave, it’s a really special place,” the vicar added.

    “It’s really exciting that people still identify this as being their church.

    “And churches are designed to be a community hub and a cultural hub and it’s great that we’re getting new, old and familiar faces returning.”

    @clopezphotography A side view of two members of the Staves singing and playing guitar with a black background@clopezphotography

    The Staves were among the first artists to appear at St Peter’s Church

    For the musicians, it makes a change from typical concert venues.

    Folk duo The Staves described the church as “a gorgeous space”.

    Camilla Staveley-Taylor said: “It’s just a beautiful room – really large, high ceilings and loads of reverb, which is everything you want when you’re singing harmonies together.

    “It makes one voice sound huge. And it makes two voices sound even bigger.”

    They admit playing in a church can be testing.

    Her sister Jessica said: “I think the challenge sometimes is to make the audience relax, because there’s a certain mindset that if you’re going into church, you’re going to be quiet and well behaved.

    “So I think we try and just put people at ease and say, ‘it’s a gig, we can chill’.

    Basher Eyre / Geograph Exterior view of St Peters - a large gothic-style stone church with a wooden porch leading to the street. The church has a pitched roof and two small pointed turrets either side of the gable end but it has no spire.Basher Eyre / Geograph

    The 19th Century church is known as ‘Poole’s cathedral’

    Figures from the Music Venue Trust show that on average two grassroots music venues per month are permanently closing across the UK, and over two fifths ran at a loss in the last year.

    Camilla Staveley-Taylor said: “Especially post-Covid, lots of the small and mid-sized venues died out

    “They’re just the lifeblood of what we do. We need them,

    “Especially as people don’t buy records anymore, playing live is incredibly important and having a place to do that and new places like this is really, really important.”

    With forthcoming acts including Tom Smith from Editors, Fionn Regan and Chartreuse, promoter Ali Tillett is already looking at booking dates well into 2026.

    “There isn’t anything of this size in terms of venue in the local area, and that’s why they love it,” he said.

    “It’s very hard to find amazing spaces. And that’s the best thing about this place is it’s unique.

    “And just seeing from the first concert how people come into the church and how they embrace it is remarkable and it’s so lovely to see.”

    Continue Reading

  • see what’s predicted for the red-hot HSBC share price over the next 12 months

    see what’s predicted for the red-hot HSBC share price over the next 12 months

    Image source: Getty Images

    The HSBC (LSE: HSBA) share price has been cooking with gas lately. It’s up 45% over the past 12 months and more than 200% over five years, with dividends on top.

    It’s not the only FTSE 100 bank to deliver strong gains. Barclays, Lloyds, and NatWest have also climbed hard. Yet HSBC offers something different, as it’s a play on Asia, where it earns around 55% of its revenues. The surprising thing is how robust it’s been, powering ahead even as China’s banking sector and property market struggle.

    It’s even withstood growing tensions between Beijing and Washington. A few years ago, I decided to avoid HSBC for fear of the political fallout. Given subsequent stellar performance, that has to go down as a mistake. The bank has tried to manage the east-west split by effectively splitting into two operations. That’s given it some breathing space, but the danger hasn’t disappeared. Being listed in London and tied to Beijing is never going to be straightforward.

    HSBC’s half-year results on 30 July showed profit falling by $5.7bn to $15.8bn, amid a $2.1bn hit from its stake in China’s Bank of Communications. It also took a $400m knockback on Hong Kong’s commercial property market, where oversupply continues to drag on rents and values.

    The board nonetheless announced another bumper $3bn share buyback and said it was well-placed to handle ongoing uncertainty, including the threat of tariffs. Lending demand may stay muted for the rest of the year, but management expects its wealth division to power on.

    It was hard to get a proper grip on the numbers, which were skewed by one-off items. This is a sprawling operation, and investors like me can only get a loose handle on how things are really going. That applies to every bank, but even more so with a global behemoth like HSBC. Trade, geopolitics, macro economics threats, regulatory issues – there’s always a threat to the banks but HSBC’s are on a bigger scale than its UK-focused rivals.

    HSBC shares still look reasonably priced even after their strong run. The stock trades on a trailing price-to-earnings ratio of 10.3, while the price-to-book value stands at 0.9.

    Income seekers may be tempted. HSBC is forecast to yield 5.2% next year, with cover of 2.1. The share buybacks should add further shareholder value. Operating margins of 44.6% impressed in the latest period, and forecasts suggest they could hit 49.6% in the year ahead.

    After such a strong rally, HSBC surely has to pause for breath. Analysts seem to think we’re there. Consensus forecasts don’t expect much movement from today’s price of around 961p over the next year. Growth forecasts are healthier for Barclays, Lloyds, and NatWest, typically around the 15% mark.

    Of the 19 analysts covering HSBC, just six rate it a Buy, while 12 suggest Holding. Only one says Sell. After its rise, HSBC may be due a quieter spell. I’d suggest keeping an eye on it, and maybe even considering buying on a dip. As ever, with a long-term view.

    The post Forecast: see what’s predicted for the red-hot HSBC share price over the next 12 months appeared first on The Motley Fool UK.

    More reading

    HSBC Holdings is an advertising partner of Motley Fool Money. Harvey Jones has positions in Lloyds Banking Group Plc. The Motley Fool UK has recommended Barclays Plc, HSBC Holdings, and Lloyds Banking Group Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

    Motley Fool UK 2025

    Continue Reading

  • ‘Overwhelming support’ for Dolly Mavies after JD Vance walkout

    ‘Overwhelming support’ for Dolly Mavies after JD Vance walkout

    Dave GilyeatBBC Introducing / BBC News Online

    Tess Viera Photography Dolly Mavies next to a tree, the leaves touching her head. She has long fair hair and blue eyes. She wears a black top with a white, feathery jacket.Tess Viera Photography

    Dolly Mavies says her band were “suspicious” because of heavy security at the gig venue

    “It was quite a small action but it had a really big ripple effect.”

    Dolly Mavies found herself at the centre of worldwide media attention when she pulled out of a gig after a tip-off the US Vice-President JD Vance could be attending.

    The folk-rock singer-songwriter and her band chose to leave the venue in Daylesford, near Kingham, and she says she was inundated with supportive messages and received a big boost in social media followers after news of their decision spread across the globe.

    Someone familiar with the vice-president’s plans has told the BBC he did not attend the gig, and had never planned to, though it has been widely reported that he was at the venue that day.

    The north Oxfordshire musician, whose real name is Molly Davies, says she and her band were “suspicious” when they turned up at the venue, situated in a farm shop and there was a “lot of security around, which there isn’t normally, and then a huge convoy of police motorbikes and very big cars”.

    Afterwards Molly posted a short video about her experience online, and “shared it with a few followers and people we know, and then it went into the news, and made its way all the way to the White House”.

    Sam Bennett Photography Dolly Mavies in a forest. She wears a black top and a green patterned cardigan. Her hair is lightly blowing in the breeze.Sam Bennett Photography

    The folk-rock singer-songwriter released her debut album last year

    Molly says this exposure led to her receiving “wonderful comments and support from people all across the world”.

    She adds: “Obviously there’s an overwhelming sense of support in America… I think for a lot of American people there’s a lot of uncertainty, and a lot of people are scared, and it was amazing to feel like they’d been heard.”

    Molly also received some comments accusing her of a PR stunt.

    “We definitely didn’t do that at all,” she says. “If we were that clever we would have done something before now.”

    Allow Google YouTube content?

    This article contains content provided by Google YouTube. We ask for your permission before anything is loaded, as they may be using cookies and other technologies. You may want to read  and  before accepting. To view this content choose ‘accept and continue’.

    Molly, who released her debut album The Calm & The Storm last year, says though she received criticism for her actions, “nobody’s ever going to agree with everybody, and that’s totally fine”.

    “It riled some people up and that’s for them to decide… but I do think it’s really interesting because in the grand scheme of things we just chose not to do something.

    “We could’ve done something much more extravagant… leaving is the most peaceful way of protest in some way.”

    PA Media JD Vance stands waving at a lectern in front of a black US military plane in a hangar at RAF Fairford. He wears a blue suit jacket and white shirt. The lectern has two microphones and the emblem of the US Vice President's Office.PA Media

    Vice President Vance’s trip included several official engagements

    Continue Reading

  • Sanjay Dutt cried for 3 hours after lung cancer diagnosis; Rakesh Roshan helped him get treatment post US visa rejection | Hindi Movie News

    Sanjay Dutt cried for 3 hours after lung cancer diagnosis; Rakesh Roshan helped him get treatment post US visa rejection | Hindi Movie News

    DISCLAIMER: This article contains references to cancer and the actor’s medical journey.Sanjay Dutt is one such Bollywood star who has faced many ups and downs in life, a journey so dramatic that much of it was shown in his biopic ‘Sanju’. He has never shied away from speaking about the most difficult and vulnerable chapters of his life. Among the hardest was his cancer diagnosis, a moment that left him shaken and emotional. The ‘Vaastav’ actor once opened up about how he dealt with this shocking news and found the strength to face it.

    Sanjay’s cancer was diagnosed during the lockdown period

    Speaking to YouTuber Ranveer Allahbadia on his podcast in the past, the ‘Khalnayak’ actor revealed that he was diagnosed during the lockdown and initially struggled to process the news.He said, “It was a normal day in the lockdown. When I walked up the stairs, I was totally out of breath. I had a bath, I couldn’t breathe, I didn’t know what was happening, so I called up my doctor. In the x-ray, more than half of my lungs were covered in water. They had to tap the water out. They all were hoping it was TB (tuberculosis) but it turned out to be cancer.”

    Poll

    Which aspect of Sanjay Dutt’s cancer journey do you find most impressive?

    Sanjay cried for hours thinking about family

    Sanjay Dutt had shared how overwhelmed he felt after hearing the diagnosis. He explained, “How to break it to me, it was a big issue. I could have broken somebody’s face. So, my sister came, I was like, ‘Okay, I’ve got cancer, now what?’. Then you start planning this, we’ll do this and that… But I did cry for two-three hours because I was thinking about my kids and my life and my wife and everything, these flashes come and I said, I am going to stop getting weak. First, we decided (to seek treatment in the US), but didn’t get the visa, so I said, I’ll do it here.”

    Family and Rakesh Roshan helped plan his cancer treatment

    The ‘Saajan’ actor explained how his family organised his treatment and how Rakesh Roshan, father of Hrithik Roshan, recommended a doctor.He added, “They told me that I’d lose hair and other things would happen, I’d vomit, so I told the doctor ‘mereko kuch nahi hoga’, I’ll not lose hair, I’ll not vomit, I won’t lie on the bed, and she kind of smiled. I did my chemotherapy, and I came back and I sat on that bike for one hour and I cycled, I did that day after day, everyday. After every chemo (session) I did that. It was crazy, I used to go for chemo, Dubai, and then I used to go to the badminton court and play for two-three hours.

    Dutt used fitness to regain his old self

    The ‘Agneepath’ actor revealed how he challenged cancer by taking up fitness and slowly regaining his strength. He explained that the only way to fight the disease was by challenging it. Sharing his progress, he said it had been two months since he started going to the gym, where he had lost weight, regained muscle, and was slowly returning to his old self. He added that he wanted to bring back the Sanjay Dutt everyone knew and admitted that while he had once let himself go, he would not do so again.

    Sanjay announced he is cancer-free in 2020

    In October 2020, Sanjay Dutt announced that he was cancer-free, much to the joy of his fans and well-wishers. He credited his recovery to his own resilience and the support of his family.

    Sanjay Dutt’s film projects

    On the work front, Sanjay Dutt’s recent film ‘Baaghi 4’ starring Tiger Shroff released in cinemas on September 5, 2025. His next film, the Ranveer Singh-starrer ‘Dhurandhar’, is slated for release in December 2025.


    Continue Reading

  • Tagrisso plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer

    With longer follow-up, the safety profile of Tagrisso plus chemotherapy continued to be manageable and consistent with the established profiles of the individual medicines. Grade 3 or higher adverse events (AEs) from all causes occurred in 70% of patients in the Tagrisso plus chemotherapy arm, driven by well-characterised chemotherapy-related AEs, versus 34% in the Tagrisso monotherapy arm, similar to the rates reported at the primary analysis presented at the IASLC 2023 WCLC (64% versus 27%, respectively). Discontinuation rates due to AEs and on-target toxicities were low in both trial arms (12% versus 7%).

    Notes

    NSCLC
    Lung cancer is the leading cause of cancer death among men and women, accounting for about one-fifth of all cancer deaths.1 Lung cancer is broadly split into small cell lung cancer or NSCLC, the latter accounting for 80-85% of cases.1-2 Approximately 75% of people are diagnosed with advanced NSCLC.3 Additionally, about 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia have EGFRm NSCLC.4-6

    While EGFR-tyrosine kinase inhibitors (TKI) have significantly improved outcomes in the 1st-line setting, mechanisms of resistance and disease progression are extremely common, and a significant unmet need exists in later-line settings for effective and well-tolerated treatment options.7-10

    FLAURA2
    FLAURA2 is a randomised, open-label, multi-centre, global Phase III trial in previously untreated patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) NSCLC whose tumors have EGFR exon 19 deletion or exon 21 L858R mutations. Patients were treated with Tagrisso 80mg QD oral tablets with the addition of chemotherapy (pemetrexed (500mg/m2) plus cisplatin (75mg/m2) or carboplatin (AUC5) every three weeks for four cycles, followed by Tagrisso with pemetrexed maintenance every three weeks.

    The trial enrolled 557 patients in more than 150 centres across more than 20 countries, including in the US, Europe, South America and Asia. The primary endpoint is PFS with OS as the key secondary endpoint.

    Tagrisso
    Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases. Tagrisso (40mg and 80mg QD oral tablets) has been used to treat more than one million patients across its indications worldwide and AstraZeneca continues to explore Tagrisso as a treatment for patients across multiple stages of EGFRm NSCLC.

    Tagrisso is approved as monotherapy in more than 120 countries including the US, EU, China and Japan. Approved indications include for 1st-line treatment of patients with locally advanced or metastatic EGFRm NSCLC, locally advanced or metastatic EGFR T790M mutation-positive NSCLC, adjuvant treatment of early-stage EGFRm NSCLC and locally advanced, unresectable NSCLC following platinum-based chemoradiation therapy (CRT). Tagrisso is also approved in combination with chemotherapy in more than 80 countries, including the US, EU, China and Japan, for 1st-line treatment of patients with locally advanced or metastatic EGFRm NSCLC.

    There is an extensive body of evidence supporting the use of Tagrisso in EGFRm NSCLC, and it is the only targeted therapy shown to improve patient outcomes across all stages of the disease.

    In late-stage disease, Tagrisso demonstrated improved outcomes as monotherapy in the FLAURA Phase III trial and in combination with chemotherapy in the FLAURA2 Phase III trial. Tagrisso is also being investigated in this setting in combination with Orpathys (savolitinib) in the SAFFRON Phase III trial and in combination with Datroway (datopotamab deruxtecan or Dato-DXd) in the TROPION-Lung14 and TROPION-Lung15 Phase III trials. 

    Tagrisso also showed improved outcomes in early-stage disease in the NeoADAURA and ADAURA Phase III trials and in locally advanced stages in the LAURA Phase III trial. As part of AstraZeneca’s ongoing commitment to treating patients as early as possible in lung cancer, Tagrisso is also being investigated in the early-stage adjuvant resectable setting in the ADAURA2 Phase III trial.

    AstraZeneca in lung cancer
    AstraZeneca is working to bring patients with lung cancer closer to cure through the detection and treatment of early-stage disease, while also pushing the boundaries of science to improve outcomes in the resistant and advanced settings. By defining new therapeutic targets and investigating in innovative approaches, the Company aims to match medicines to the patients who can benefit most.

    The Company’s comprehensive portfolio includes leading lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa (gefitinib); Imfinzi (durvalumab) and Imjudo (tremelimumab); Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan) in collaboration with Daiichi Sankyo; Orpathys (savolitinib) in collaboration with HUTCHMED; as well as a pipeline of potential new medicines and combinations across diverse mechanisms of action.

    AstraZeneca is a founding member of the Lung Ambition Alliance, a global coalition working to accelerate innovation and deliver meaningful improvements for people with lung cancer, including and beyond treatment.

    AstraZeneca in oncology
    AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

    The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

    AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

    AstraZeneca
    AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.

    Contacts
    For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

    Continue Reading

  • Prognostic Value of Perioperative Serum Creatinine Kinase Levels for Metachronous Colorectal Liver Metastasis

    Prognostic Value of Perioperative Serum Creatinine Kinase Levels for Metachronous Colorectal Liver Metastasis


    Continue Reading

  • Israeli forces martyr 17 in Gaza – RADIO PAKISTAN

    1. Israeli forces martyr 17 in Gaza  RADIO PAKISTAN
    2. LIVE: Israeli attacks on school, tents and homes kill at least 17 in Gaza  Al Jazeera
    3. Israel destroys second high-rise as assault on Gaza City intensifies  BBC
    4. Israeli military warns Gaza City residents to leave, bombs high-rise tower  Reuters
    5. Gaza deaths since dawn rise to 58  Dawn

    Continue Reading

  • South Korea to tighten mortgage rules in Seoul, boost housing supply – Reuters

    1. South Korea to tighten mortgage rules in Seoul, boost housing supply  Reuters
    2. S. Korea Unveils More Property Cooling Steps Amid Loan Concerns  Bloomberg
    3. Finance minister says govt. to announce measures to supply homes Sunday  The Korea Herald
    4. South Korea to announce measures to supply new homes  tripuratimes.com
    5. Greater Seoul to get 1.35 million new homes by 2030  The Korea Herald

    Continue Reading